{
    "clinical_study": {
        "@rank": "149770", 
        "acronym": "EVOTAR", 
        "arm_group": [
            {
                "arm_group_label": "Ceftriaxone", 
                "description": "Patients receiving a C3G (ceftriaxone) during the hospitalization."
            }, 
            {
                "arm_group_label": "Ceftriaxone + Fluoroquinolone", 
                "description": "ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram)."
            }, 
            {
                "arm_group_label": "Fluoroquinolones", 
                "description": "fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin)."
            }, 
            {
                "arm_group_label": "Reference", 
                "description": "A third reference group will consist of patients hospitalized in the same services as the \"case\" patients but did not receive antibiotics (60 patients). They will have an idea of \u200b\u200bpossible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
            }
        ], 
        "biospec_descr": {
            "textblock": "Stool samples will be collected on 4 separate days for patients treated with antibiotics:\n\n      T0: before treatment begins T1: at the end of treatment or discharge from the hospital T2:\n      3-6 months after the end of treatment T3: 10-14 months after the end of treatment For\n      patients receiving sequentially ceftriaxone followed by a FQ, an additional sample will be\n      collected at the end of ceftriaxone treatment.\n\n      In the reference group, stool samples will be collected:\n\n      T0: at inclusion in the study T1: at hospital discharge The purpose is to study the\n      bacterial DNA contained in the stool. No analysis will be performed on the human patient\n      DNA.\n\n      Changes in the gut microflora will be analysed by metagenomics deep sequencing performed by\n      Dushko Ehrlich (INRA, France)."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Observational study of the effects of antibiotics on commensal flora. Realization of stool\n      samples and nasal swabs before and after antibiotic therapy."
        }, 
        "brief_title": "Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bacterial Infections", 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "detailed_description": {
            "textblock": "The emergence of resistance to fluoroquinolone (FQ) and is a major problem worldwide. The\n      commensal flora is the main reservoir for antibiotic resistance. Understanding the factors\n      (environmental, patient-related, dosis-related, drug-related\u2026) involved in the emergence of\n      resistance to fluoroquinolones in the commensal flora of patients treated with a FQ, may\n      help prevent it and preserve the efficiency of these important antibiotics. Samples of\n      digestive flora will be collected from hospitalized patients before receiving a FQ or\n      Ceftriaxone, at the end of the treatment and 3 month after the end of treatment. Clinical\n      data will be collected."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria for the patients treated with antibiotics\n\n          -  Adult patient hospitalized in a participating ward of the hospital for an expected\n             duration of more than 24 hours.\n\n          -  Treatment by ceftriaxone and / or a fluoroquinolone started by the attending\n             physicians during hospitalization.\n\n          -  No hospitalization or stay in nursing home in the previous three months.\n\n          -  No use of antibiotics in the last 3 months\n\n          -  Not receiving other antibiotics than ceftriaxone or FQ\n\n          -  Informed consent\n\n        Inclusion criteria for the patients in the reference group\n\n          -  Adult patient hospitalized in a participating ward of the hospital for an expected\n             duration of more than 24 hours.\n\n          -  Not receiving any antibiotic and not expected to receive any during hospitalization\n\n          -  No hospitalization or stay in nursing home in the previous three months.\n\n          -  No use of antibiotics in the last 3 months\n\n          -  Informed consent\n\n        Exclusion criteria\n\n          -  Pregnant or nursing women\n\n          -  Patient who underwent colectomy or suffering from chronic intestinal disease\n             (inflammatory intestinal disease or short bowel syndrome)\n\n          -  Patient who used a bowel preparation solution for colonoscopy during hospitalization\n             or in the previous week.\n\n          -  Protected adult patient (deputyship or guardianship)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "-  Hospitalized patients treated with ceftriaxone and / or an oral fluoroquinolone at\n             Beaujon hospital, Clichy, France.\n\n          -  A reference group of hospitalized patients not receiving antibiotics, hospitalized in\n             the same wards as the treated patients"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031588", 
            "org_study_id": "RAFREU53"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ceftriaxone", 
                "Fluoroquinolones"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Study of commensal flora", 
            "Fluoroquinolones"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "tiphaine.goulenok@bjn.aphp.fr", 
                "last_name": "Tiphaine Goulenok, Doctor", 
                "phone": "01 40 87 52 27"
            }, 
            "facility": {
                "address": {
                    "city": "Clichy la garenne", 
                    "country": "France", 
                    "zip": "92110"
                }, 
                "name": "H\u00f4pital Beaujon"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "4", 
        "official_title": "Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.", 
        "overall_contact": {
            "email": "vdelastours@hotmail.com", 
            "last_name": "Victoire De Latours", 
            "phone": "01 57 27 75 18"
        }, 
        "overall_official": {
            "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
            "last_name": "Victoire De Latours, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the change in composition of the microbial flora in relation to the initial flora (T0), at the exit of the hospital or at the end of treatment if occurs while the patient is still hospitalized (bis T0, T1, T1 bis), 3 months after the end of treatment (T2) and one year after the end of treatment (T3).", 
            "measure": "Describe the changes in the composition of the gut microbial flora in relation to the initial flora (T0) in patients receiving antibiotics, by date of sampling, treatment received, dose, duration of therapy, ward, and duration of hospital stay.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "A secondary endpoint is to describe the changes in the gut microbiota of hospitalized patients not receiving antibiotics.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}